8-K - Picard Medical, Inc. (0002030617) (Filer)

DEF 14A - Picard Medical, Inc. (0002030617) (Filer)

PRE 14A - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

424B4 - Picard Medical, Inc. (0002030617) (Filer)

A pioneer in modified risk tobacco products, Philip Morris International is the only company to have received a modified risk marketing claim for an electronic nicotine device. FDA concludes "Evidence continues to support the modified exposure claim that ‘Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body's exposure to harmful or potentially harmful chemicals.'" Experts from Philip Morris International Inc. (NYSE:PM) presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC). The committee, comprised of independent scientific researchers, provides nonbinding recommendations to

TAICHUNG CITY, Taiwan, Sept. 22, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (NASDAQ:YMAT) ("J-Star" or the "Company"), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services, today announced that Sam Van has been named Chief Executive Officer of J-Star, effective October 1. Mr. Van succeeds Jonathan Chiang, who will continue to serve as Chairman of the Board with a focus on driving continued market innovation and key customers. Mr. Van joins at a pivotal moment for J-Star. Following the Company's recent i

- Patent portfolio secures innovation for the future of heart replacement - TUCSON, Ariz., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced the strengthening of its intellectual property portfolio with the recent grant of U.S. Patent No. 12,383,722 B2 covering systems and methods related to its next-generation SynCardia Total Artificial Heart (STAH), the "Emperor." This recently granted patent, relating to the apparatus, systems, and methods for enabling a next-generation total artificial heart w

Strong commercial momentum driven by higher product sales – Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology - TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 2025. In early September, Picard successfully closed its initial public offering, raising gross proceeds of $19.5 million. "Our second quarter results reflect strong sales growth for the SynCardia total artif

TUCSON, Ariz., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced the appointment of two new members that will serve on its Board of Directors, Sam Van and George Ye. Both were appointed following the closing of the initial public offering and have deep leadership experience in complementary areas to advise the company in its next stage as a public company. "We are thrilled to welcome Sam and Geore to our Board," said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc. "Sam bri

TUCSON, Ariz., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), today announced that the underwriters of its previously announced initial public offering of common stock, par value $0.0001 per share (the "Common Stock") have exercised their over-allotment option in full on September 5, 2025, resulting in the issuance of an additional 637,500 shares of Common Stock at a public offering price of $4.00 per share, for gross proceeds of $2,550,000, before deducting underwriting discounts and estimated offering expenses. The shares began trading on the NYSE American, LLC ("NYSE American") under the ticker symbol "PMI" on August 29, 2025. WestPark C

TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will present in-person at the H.C. Wainwright 27th Annual Global Investment Conference being held both in-person and virtually from September 8 -10, 2025 at the Lotte New York Palace Hotel. Presentation information is below: H.C. Wainwright Annual Global Investment Conference Presentation date: September 10thPresentation time: 1:30 pm Format: in-person; live, webcasted Company presentation with reply To listen to the presentation live or via replay, please visit the Investor Overview/Events section of the

TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), today announced that it closed its initial public offering of 4,250,000 shares of common stock, par value $0.0001 per share (the "Common Stock") at $4.00 per share (the "Offering"). The Company has granted the underwriters an option, within 30 days from the closing date of the Offering, to purchase up to an additional 637,500 shares of Common Stock the public offering price, less underwriting discounts, to cover over-allotment, if any. The gross proceeds from the offering were $17 million, before deducting underwriting discounts and estimated offering expenses. The shares began tr